Iloprost Zentiva K.S.

Iloprost, the active ingredient in Iloprost Zentiva K.S., is a prostacyclin analog presented as an inhalation solution for inhalation use. It treats pulmonary arterial hypertension in adult patients by inducing selective vasodilation of the pulmonary arteries, improving exercise capacity and delaying disease progression.

GNH USA supplies Iloprost Zentiva K.S. as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company ensures compliance with EU regulatory standards and provides reliable logistics for global distribution.

Iloprost acts on the prostacyclin pathway to manage diseases characterized by elevated pulmonary vascular resistance. - Pulmonary arterial hypertension: improves functional class, exercise capacity and delays clinical worsening. - Chronic thromboembolic pulmonary hypertension: used as adjunct therapy to enhance hemodynamic parameters. - Pulmonary hypertension associated with connective‑tissue disease: may be considered to alleviate symptoms and improve quality of life.

Iloprost may cause a range of adverse reactions, most of which are related to its vasodilatory activity.

Common Side Effects: - Cough or throat irritation - Headache - Flushing or warmth sensation - Nausea or dyspepsia - Dizziness or light‑headedness - Nasal congestion

Serious or Rare Side Effects: - Significant hypotension - Pulmonary edema - Bleeding or hemorrhage - Severe chest pain or angina - Arrhythmias - Anaphylactic or severe allergic reactions

Before initiating therapy, clinicians should assess individual risk factors and monitor patients closely. - Blood pressure monitoring: check for hypotension after each dose. - Bleeding risk: evaluate concomitant anticoagulant use and history of hemorrhage. - Concomitant vasodilators: avoid or use with caution to prevent additive hypotensive effects. - Hepatic impairment: dose adjustment may be required in patients with liver dysfunction. - Pregnancy and lactation: safety not established; use only if potential benefit justifies risk. - Store at room temperature: keep in original container, protect from moisture and light.

Iloprost can interact with several medication classes, influencing its safety profile.

Major Interactions (Avoid): - Other prostacyclin analogs (e.g., epoprostenol, treprostinil): risk of severe hypotension. - Potent vasodilators (e.g., nitroglycerin, hydralazine): additive blood‑pressure lowering effect.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin, heparin): increased bleeding tendency. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil, tadalafil): may enhance pulmonary vasodilation. - Beta‑blockers: may blunt hemodynamic response to Iloprost.